China Pharma Holdings, Inc. (CPHI) stock
CPHINYSEPharmaceutical PreparationsFiscal year ends December 31
$0.50+0.02 (+4.17%)
Close on Nov 17, 2026Market cap $21.51MP/E –Yield –
China Pharma gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
China Pharma's gross profit for the twelve months ending Sep 30, 2026 was $611.80K. For fiscal 2025 it was -$131.95K. The highest annual figure on record is $30.28M in fiscal 2010.
Annual gross profit
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$131.95K | – |
| FY2024 | Dec 31, 2024 | -$1.99M | – |
| FY2023 | Dec 31, 2023 | -$281.09K | – |
| FY2022 | Dec 31, 2022 | -$493.92K | -241.4% |
| FY2021 | Dec 31, 2021 | $349.27K | -82.1% |
| FY2020 | Dec 31, 2020 | $1.95M | +31.8% |
| FY2019 | Dec 31, 2019 | $1.48M | -24.9% |
| FY2018 | Dec 31, 2018 | $1.97M | -20.0% |
| FY2017 | Dec 31, 2017 | $2.47M | -23.3% |
| FY2016 | Dec 31, 2016 | $3.22M | +119.8% |
| FY2015 | Dec 31, 2015 | $1.46M | -45.1% |
| FY2014 | Dec 31, 2014 | $2.67M | – |
| FY2013 | Dec 31, 2013 | -$480.92K | -103.4% |
| FY2012 | Dec 31, 2012 | $14.08M | -51.4% |
| FY2011 | Dec 31, 2011 | $28.99M | -4.3% |
| FY2010 | Dec 31, 2010 | $30.28M | – |
Quarterly gross profit
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $91.97K | – |
| Q2 FY2026 | Jun 30, 2026 | $83.57K | – |
| Q1 FY2026 | Mar 31, 2026 | $285.49K | – |
| Q4 FY2025 | Dec 31, 2025 | $150.78K | – |
| Q3 FY2025 | Sep 30, 2025 | -$59.65K | – |
| Q2 FY2025 | Jun 30, 2025 | -$87.01K | – |
| Q1 FY2025 | Mar 31, 2025 | -$136.06K | – |
| Q4 FY2024 | Dec 31, 2024 | -$160.59K | – |
| Q3 FY2024 | Sep 30, 2024 | -$519.65K | – |
| Q2 FY2024 | Jun 30, 2024 | -$1.02M | – |
| Q1 FY2024 | Mar 31, 2024 | -$290.02K | -263.0% |
| Q4 FY2023 | Dec 31, 2023 | -$79.16K | -285.5% |
| Q3 FY2023 | Sep 30, 2023 | -$233.19K | – |
| Q2 FY2023 | Jun 30, 2023 | -$146.66K | – |
| Q1 FY2023 | Mar 31, 2023 | $177.92K | – |
| Q4 FY2022 | Dec 31, 2022 | $42.68K | -85.9% |
| Q3 FY2022 | Sep 30, 2022 | -$137.76K | – |
| Q2 FY2022 | Jun 30, 2022 | -$229.38K | -423.1% |
| Q1 FY2022 | Mar 31, 2022 | -$169.46K | -162.1% |
| Q4 FY2021 | Dec 31, 2021 | $301.94K | -46.2% |
| Q3 FY2021 | Sep 30, 2021 | -$296.40K | -728.0% |
| Q2 FY2021 | Jun 30, 2021 | $71.00K | -93.8% |
| Q1 FY2021 | Mar 31, 2021 | $272.73K | +40.3% |
| Q4 FY2020 | Dec 31, 2020 | $561.47K | +94.0% |
| Q3 FY2020 | Sep 30, 2020 | $47.20K | -87.3% |
| Q2 FY2020 | Jun 30, 2020 | $1.15M | +603.0% |
| Q1 FY2020 | Mar 31, 2020 | $194.44K | -70.4% |
| Q4 FY2019 | Dec 31, 2019 | $289.35K | – |
| Q3 FY2019 | Sep 30, 2019 | $372.76K | -27.3% |
| Q2 FY2019 | Jun 30, 2019 | $163.55K | -71.8% |
| Q1 FY2019 | Mar 31, 2019 | $656.53K | -37.7% |
| Q4 FY2018 | Dec 31, 2018 | -$170.88K | -125.1% |
| Q3 FY2018 | Sep 30, 2018 | $512.55K | +21.6% |
| Q2 FY2018 | Jun 30, 2018 | $579.48K | -10.6% |
| Q1 FY2018 | Mar 31, 2018 | $1.05M | +46.8% |
| Q4 FY2017 | Dec 31, 2017 | $680.80K | -61.0% |
| Q3 FY2017 | Sep 30, 2017 | $421.54K | – |
| Q2 FY2017 | Jun 30, 2017 | $648.36K | – |
| Q1 FY2017 | Mar 31, 2017 | $717.85K | – |
| Q4 FY2016 | Dec 31, 2016 | $1.75M | – |
See a number that looks wrong?